308P - Role of CXCR4 and VLA-4 expression as prognostic markers in Egyptians acute lymphoblastic leukemia patients

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Leukaemia
Translational Research
Presenter Mohamed Elbaiomy
Citation Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526
Authors S. Aref1, M. Sabry El-Ghonemy1, A. El-Sedik2, E. Azmy3, M.A. Elbaiomy4
  • 1Clinical Pathology, Oncology Centre Mansura University, 01258 - Dakahlia/EG
  • 2Clinical Pathology, Mansoura University, 01258 - Dakahlia/EG
  • 3Clinical Hematology, Oncology Centre Mansura University, 01258 - Dakahlia/EG
  • 4Medical Oncology, Oncology Centre Mansura University, 050 - Dakahlia/EG

Abstract

Aim/Background

Assess the prognostic impact of CXCR4 and VLA-4 expression on acute lymphoblastic leukemia patients.

Methods

VLA-4 and CXCR4 expressions was performed by flowcytometry

Results

This study was conducted on 62 ALL patients (17-65 years) with of 42 males and 20 females. The CXCR4 was highly expressed in 26 (41.9%) and the VLA4 was highly expressed in 22 (35.5%) however combined high CXCR4 and low VLA-4 expression was observed in 23 patients (37.1%). High CXCR4 expression was significantly associated with high WBCs and high LDH. Patients with high CXCR4 expression was significantly associated with longer time to CR (mean ± SD; 64.3 ± 34.1 days) versus (mean ± SD; 38.3 ± 24.4 days) for patients with low CXCR4 expression with P value 0.001. High CXCR4 expression was significantly associated with short DFS (P = 0.017) and short OS (P = 0.048). Low VLA4 expression was significantly associated with shorter OS (P = 0.04). Patients with combined high CXCR4 expression and low VLA4 expression were significantly associated with high WBCs, high LDH, shorter DFS (P= 0.021) and shorter OS (P 0.01) versus rest of patients.

Conclusions

In conclusion, patients with high CXCR4 and / or low VLA-4 expression were associated with poor DFS and poor OS and the prognostic power increased when the combination of both expressions was applied.

Clinical trial identification

We recommend further investigation to asses there use as therapeutic targets for patients with ALL.

Disclosure

All authors have declared no conflicts of interest.